Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Receivables: 2014-2024

Historic Change in Receivables for vTv Therapeutics (VTVT) over the last 4 years, with Dec 2024 value amounting to -$180,000.

  • vTv Therapeutics' Change in Receivables fell 276.47% to -$180,000 in Q4 2024 from the same period last year, while for Dec 2024 it was -$40,000, marking a year-over-year decrease of 260.00%. This contributed to the annual value of -$40,000 for FY2024, which is 43.66% up from last year.
  • Per vTv Therapeutics' latest filing, its Change in Receivables stood at -$180,000 for Q4 2024, which was down 181.25% from -$64,000 recorded in Q3 2024.
  • In the past 5 years, vTv Therapeutics' Change in Receivables ranged from a high of $928,000 in Q3 2021 and a low of -$871,000 during Q4 2021.
  • In the last 3 years, vTv Therapeutics' Change in Receivables had a median value of -$20,000 in 2022 and averaged $555.56.
  • Over the last 5 years, vTv Therapeutics' Change in Receivables had its largest YoY gain of 6,528.57% in 2021, and its largest YoY loss of 704.86% in 2021.
  • Quarterly analysis of 5 years shows vTv Therapeutics' Change in Receivables stood at $144,000 in 2020, then crashed by 704.86% to -$871,000 in 2021, then surged by 113.32% to $116,000 in 2022, then fell by 12.07% to $102,000 in 2023, then crashed by 276.47% to -$180,000 in 2024.
  • Its last three reported values are -$180,000 in Q4 2024, -$64,000 for Q3 2024, and -$675,000 during Q2 2024.